Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) reached a new 52-week low on Monday . The stock traded as low as $51.00 and last traded at $51.00, with a volume of 10 shares changing hands. The stock had previously closed at $54.00.
Basilea Pharmaceutica Price Performance
The stock has a 50 day moving average of $53.15 and a 200-day moving average of $52.84. The company has a debt-to-equity ratio of 5.70, a quick ratio of 3.27 and a current ratio of 4.10.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- What is a Bond Market Holiday? How to Invest and Trade
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- Financial Services Stocks Investing
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- 3 Warren Buffett Stocks to Buy Now
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
